A paradigm shift for human health

News

1
2
3
4
5
6
7
8

Cellectis CEO Selected as Speaker for 2017 Milken Institute Global Conference

Learn more

Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting

Learn more

Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.

Learn more

Cellectis to Present at the 2017 Annual Conference of the American Association for Cancer Research

Learn more

Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

Learn more

Five Additional Leading Physicians to Join Cellectis Clinical Advisory Board

Learn more

Cellectis to Present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 1:30pm ET in New York

Learn more

FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.

Learn more

Four Prominent Physicians to Join Cellectis Clinical Advisory Board

Learn more

Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions

Learn more

Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN

Learn more

Cellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT

Learn more

Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN

Learn more

Cellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT

Learn more

Cellectis Announces Conference Call To Discuss Recent Recombinant DNA Advisory Committee (RAC) Meeting

Learn more

Cellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN

Learn more

Scientific publication

Design of chimeric antigen receptors with integrated controllable transient functions
Alexandre Juillerat, Alan Marechal, Jean-Marie Filhol, Julien Valton, Aymeric Duclert, Laurent Poirot & Philippe Duchateau

Scientific Reports 6, Article number: 18950 (2016) doi:10.1038/srep18950

Read the article

Genome editing

Genome editing is a broadly applicable approach for efficient and targeted modification of genetic information of living organisms.

Learn more

OUR PATENTS

103 patent families
66 granted patents
302 patent applications
 
Learn more

READ

our scientific publications

Learn more